---
title: "Abbvie, Merck, and other companies will announce the U.S. drug pricing agreements. (Reuters)"
description: "Abbvie, Merck, and other companies will announce the U.S. drug pricing agreements. (Reuters)"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270296422.md"
published_at: "2025-12-19T11:18:43.000Z"
---

# Abbvie, Merck, and other companies will announce the U.S. drug pricing agreements. (Reuters)

Abbvie, Merck, and other companies will announce the U.S. drug pricing agreements. (Reuters)

### Related Stocks

- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)
- [ABBV.US - Abbvie](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | [Link](https://longbridge.com/en/news/274841608.md) |
| (ABBV) AbbVie Expects 2026 Adjusted EPS Range $14.37 to $14.57, vs. FactSet Est of $14.27 | (ABBV) AbbVie Expects 2026 Adjusted EPS Range $14.37 to $14.57, vs. FactSet Est of $14.27 | [Link](https://longbridge.com/en/news/274820805.md) |
| AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch | AbbVie (ABBV) is conducting a Phase 2 clinical trial for AGN-151607-DP, a botulinum toxin-based therapy aimed at improvi | [Link](https://longbridge.com/en/news/275926867.md) |
| BUZZ-Street View: Immunology strength holds at AbbVie despite aesthetics drag | AbbViereported strong sales of immunology drugs Skyrizi and Rinvoq, raising its 2025 profit forecast despite ongoing str | [Link](https://longbridge.com/en/news/264024900.md) |
| AbbVie says Trump pressing for larger Medicare drug price cuts | AbbVie reported that the Trump administration is advocating for larger Medicare drug price cuts, with discounts potentia | [Link](https://longbridge.com/en/news/263784748.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.